UniCredit Bank (Austria)

Zeta Biopharma is a plant construction company in Austria with 237 employees providing process technology for biopharmaceutical applications by supplying global pharmaceutical companies with individually designed plants.

Zeta’s production plants are used by large pharma companies to develop vaccines, injections and pharmaceutical drugs used to fight diseases worldwide. The company is one of only two in Europe to use freeze and thaw containers for storage and transport of substances for the pharmaceutical industry. These liquids can be frozen in a controller storage facility for years and are often sent to markets worldwide.

The plants are manufactured in modular design with state-of-the-art equipment at the production site in Lieboch, Graz, and are dispatched to operation sites across Europe and beyond under sterile conditions  where they are then installed and commissioned by qualified staff and engineers.

UniCredit Bank Austria is the leading bank in Austria and Central and Eastern Europe. The bank has been a member of UniCredit since 2005. Bank Austria is an EIF partner under the Risk Sharing Initiative (RSI) thanks to its SME strategy, financial standing, risk models, origination power, marketing initiatives and proved, in particular its know-how in export- and investment promotion funding and advisory. During the financial and economic crisis, Bank Austria was the only major bank in Austria that did not use state aid to strengthen its capital. Bank Austria supports Austria’s economy by providing special offers for innovative SMEs – from advisory services in the start-up phase to financing solutions including funding all the way to business planning and succession planning.

The EUR 2,5m working capital loan granted by UniCredit Bank Austria with a 50% EIF guarantee under the RSI covers Zeta’s high working capital requirements during the long lead times in plant engineering and manufacturing. The RSI guarantee funded by the EU Commission and the EIB perfectly complements the national research promotion schemes in Austria and helps the company to implement additional R&D projects and to achieve faster growth.

• Company: Zeta Biopharma, Austria
• Type of business: plant construction company
• EU-supported loan through UniCredit Bank Austria:  EUR 2,5m

For further information about EIF intermediaries in Austria, please refer to:
http://www.eif.org/what_we_do/where/at